Estrogen receptor β transcript variants associate with oncogene expression in endometrial cancer

International Journal of Molecular Medicine

Volumn 29, Issue 6, 2012, Pages 1127-1136

  Häring, Julia ^a   Skrzypczak, Maciej ^a,b   Stegerer, Anette ^a   Lattrich, Claus ^a   Weber, Florian ^a   Gor̈se, Regina ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Alternative splicing; Endometrial cancer; Estrogen receptor

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR BETA; RECEPTOR SUBTYPE; SMALL INTERFERING RNA;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; ONCOGENE; ONCOGENE MYBL2; ONCOGENE NEU; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CELL CYCLE PROTEINS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; ONCOGENES; POSTMENOPAUSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TRANS-ACTIVATORS;

EID: 84860499079     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.929     Document Type: Article

References (61)

1. Younes M and Honma N: Estrogen receptor β. Arch Pathol Lab Med 135: 63-66, 2011.
2. Leung YK, Mak P, Hassan S and Ho SM: Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 103: 13162-13167, 2006. (Pubitemid 44338933)
3. Lewandowski S, Kalita K and Kaczmarek L: Estrogen receptor β. Potential functional signifcance of a variety of mRNA isoforms. FEBS Lett 524: 1-5, 2002. (Pubitemid 34804824)
4. Peng B, Lu B, Leygue E and Murphy LC: Putative functional characteristics of human estrogen receptor-β isoforms. J Mol Endocrinol 30: 13-29, 2003. (Pubitemid 36305253)
5. Poola I, Abraham J and Baldwin K: Identification of ten exon deleted ERβ mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α. FEBS Lett 516: 133-138, 2002. (Pubitemid 34311949)
6. Cirisano FD and Karlan BY: The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 3: 99-105, 1996. (Pubitemid 26139457)
7. Tsuda H, Hashiguchi Y, Inoue T and Yamamoto K: Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 65: 159-166, 2003. (Pubitemid 37025978)
8. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
9. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP and Saunders PT: Wild-type estrogen receptor (ERβ1) and the splice variant (ERßcx/β2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 87: 5265-5273, 2002. (Pubitemid 35316373)
10. Matsuzaki S, Uehara S, Murakami T, Fujiwara J, Funato T and Okamura K: Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real-time reverse transcription-polymerase chain reaction assay. Fertil Steril 74: 753-759, 2000.
11. Matsuzaki S, Fukaya T, Suzuki T, Murakami T, Sasano H and Yajima A: Oestrogen receptor α and β mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 5: 559-564, 1999. (Pubitemid 29251636)
12. Brandenberger AW, Lebovic DI, Tee MK, Ryan IP, Tseng JF, Jaffe RB and Taylor RN: Oestrogen receptor (ER)-α and ER-β isoforms in normal endometrial and endometriosis derived stromal cells. Mol Hum Reprod 5: 651-655, 1999. (Pubitemid 29317755)
13. Utsunomiya H, Suzuki T, Harada N, Ito K, Matsuzaki S, Konno R, Sato S, Yajima A and Sasano H: Analysis of estrogen receptor α and β in endometrial carcinomas: correlation with ERβ and clinicopathologic findings in 45 cases. Int J Gynecol Pathol 19: 335-334, 2000.
14. Zhao C, Dahlman-Wright K and Gustafsson JA: Estrogen receptor β: an overview and update. Nucl Recept Signal 6: e003, 2008.
15. Treeck O, Lattrich D, Springwald A and Ortmann O: Estrogen receptor β exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120: 557-565, 2010.
16. Morani A, Warner M and Gustafsson JA: Biological functions and clinical implications of estrogen receptors α and β in epithelial tissues. J Intern Med 264: 128-142, 2008. (Pubitemid 351962577)
17. Leygue E, Dotzlaw H, Watson P and Murphy L: Altered estrogen reseptor α and β mRNA expression during human breast tumorigenesis. Cancer Res 58: 3197-3201, 1998. (Pubitemid 28371051)
18. Iwao K, Miyoshi Y, Egawa C, Ikeda N and Noguchi S: Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 88: 733-736, 2000.
19. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P and Rochefort H: Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumours. Cancer Res 61: 2537-2541, 2001. (Pubitemid 32685835)
20. Cai HB, Zhou YF, Wang BC and Gong LL: Expression of estrogen receptors α and β protein in endometrial carcinoma. Cancer Therapy 6: 907-912, 2008.
21. Šmuc T and Rizner T: Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 301: 74-82, 2009.
22. Hu K, Zhong G and He F: Expression of estrogen receptors ERα and ERβ in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 15: 537-541, 2005. (Pubitemid 40705553)
23. Fujimoto J, Sakaguchi H, Aoki I, Toyoki I and Tamaya T: Clinical implications of the expression of estrogen receptor-α and -β in primary and metastatic lesions of uterine endometrial cancers. Oncology 62: 269-277, 2002. (Pubitemid 34639061)
24. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS and Friese K: Normal and malignant human endometrium express immunohistochemically estrogen receptor α (ER-α), estrogen receptor β (ER-β) and progesterone receptor (PR). Anticancer Res 25: 1679-1686, 2005. (Pubitemid 40896785)
25. Takama F, Kanuma T, Wang D, Kagami I and Mizunuma H: Oestrogen receptor β expression and depth of myometrial invasion in human endometrial cancer. Br J Cancer 84: 545-549, 2001. (Pubitemid 32215884)
26. Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H and Hollema H: Expression of estrogen receptor-α and -β and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112: 537-542, 2009.
27. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R and Ortmann O: Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 110: 507-520, 2008. (Pubitemid 351962596)
28. Leguye E, Dotslaw H, Watson PH and Murphy LC: Expression of estrogen receptor β1, β2 and β5 messenger RNAs in human breast tissues. Cancer Res 59: 1175-1179, 1999. (Pubitemid 29136241)
29. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP and Speirs V: Nuclear and cytoplasmatic expression of ERβ1, ERβ2 and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14: 5228-5235, 2008.
30. Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R and Kaczmarek L: Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium. Int J Cancer 110: 783-787, 2004. (Pubitemid 38758502)
31. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A and Majumdar S: Estrogen receptor β1 and the β2/βcx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 17: 905-913, 2007. (Pubitemid 47063317)
32. Scholl S, Beuzeboc P and Pouillart P: Targeting HER2 in other tumor types. Ann Oncol 12 (Suppl 1): S81-S87, 2001. (Pubitemid 32750590)
33. Berchuk A and Boyd J: Molecular basis of endometrial cancer. Cancer 76: 2034-2040, 1995.
34. Samarnthai N, Hall K and Yeh IT: Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010: 162363, 2010.
35. Ejskjaer K, Sørensen BS, Poulsen SS, Forman A, Nexø E and Mogensen O: Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 104: 158-167, 2007. (Pubitemid 46054118)
36. Umekita Y, Souda M, Ohi Y, Sagara Y, Rai Y, Takahama T and Yoshida H: Expression of wild-type estrogen receptor β protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathol Int 56: 423-427, 2006. (Pubitemid 44035906)
37. Choi Y and Pinto M: Estrogen receptor β in breast cancer: associations between ERβ, hormonal receptors, and other prognostic biomarkers. Appl Immunohistochem Mol Morphol 13: 19-24, 2005. (Pubitemid 40283798)
38. Lattrich C, Juhasz-Boess I, Ortmann O and Treeck O: Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor β1. Oncol Rep 19: 811-817, 2008. (Pubitemid 351330453)
39. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN and Saunders PT: Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERa. BMC Cancer 9: 330, 2009.
40. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL and Ho SM: Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17: 675-689, 2010.
41. Sala A: MYBL2, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer 41: 2479-2484, 2005.
42. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC and Perou CM: In vitro and in vivo analysis of MYBL2 in basal-like breast cancer. Oncogene 28: 742-751, 2009.
43. Sala A and Calabretta B: Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc Natl Acad Sci USA 89: 10415-10419, 1992.
44. Raschellà G, Negroni A, Sala A, Pucci S, Romeo A and Calabretta B: Requirement of b-myb function for survival and differentiative potential of human neuroblastoma cells. J Biol Chem 270: 8540-8545, 1995.
45. Sala A, Casella I, Bellon T, Calabretta B, Watson RJ and Peschle C: B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. J Biol Chem 271: 9363-9367, 1996. (Pubitemid 26139921)
46. Seong HA, Manoharan R and Ha H: MYBL2 positively regulates serine-threonine kinase receptor-associated protein (STRAP) activity through direct interaction. J Biol Chem 286: 7439-7456, 2011.
47. Tang L, Zhang Y, Pan H, Luo Q, Zhu XM, Dong MY, Leung PC, Sheng JZ and Huang HF: Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell. Reprod Biol Endocrinol 7: 144, 2009.
48. Arnold A and Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23: 4215-4224, 2005. (Pubitemid 46211327)
49. Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedullà F and Alama A: Increased cyclin-D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 5: 1837-1842, 1999. (Pubitemid 29334466)
50. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG and Korc M: Increased cyclin-D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 55: 363-369, 1998. (Pubitemid 28279682)
51. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV and Arnold A: Cyclin-D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin-D1 oncogene. Mod Pathol 8: 560-567, 1995.
52. Ito K, Sasano H, Yoshida Y, Sato S and Yajima A: Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res 18: 1661-1664, 1998. (Pubitemid 28342576)
53. Nikaido T, Li SF, Shiozawa T and Fujii S: Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78: 1248-1253, 1996. (Pubitemid 26303891)
54. Özuysal S, Öztürk H, Bilgin T and Filiz G: Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Arch Gynecol Obstet 271: 123-126, 2005. (Pubitemid 40476242)
55. Yam CH, Fung TK and Poon RYC: Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326, 2002.
56. Milde-Langosch K, Bamberger AM, Goemann C, Rössing E, Rieck G, Kelp B and Löning T: Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 127: 537-544, 2001. (Pubitemid 32757487)
57. Nishimura Y, Watanabe J, Jobo T, Kato N, Fujisawa T, Kamata Y and Kuramoto H: Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Res 24: 2185-2191, 2004. (Pubitemid 39166293)
58. Sivridis E and Giatromanolaki A: The pathogenesis of endometrial carcinomas at menopause: facts and figures. J Clin Pathol 64: 553-560, 2011.
59. Yasumizu T, Ogawa K and Kato J: Comparison of the clinicopathological characteristics of premenopausal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. Jpn J Clin Oncol 26: 152-156, 1996. (Pubitemid 126472312)
60. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC Jr and Harris HA: Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-β ligands. J Med Chem 47: 5021-5040, 2004. (Pubitemid 39314900)
61. Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA and Macchia M: Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor β. J Med Chem 52: 858-867, 2009.